Rhytm
Rhythm was founded in 2008 in Boston.
Our lead asset, IMCIVREE® (setmelanotide), FDA-approved in 2020, is a precision medicine designed to treat severe obesity caused by an impairment of a pathway in the hypothalamus called the MC4R pathway.
Rhythm became a publicly traded company in 2017. Now, we have grown to more than 250 employees in North America and Europe. With a robust clinical trials program, we remain poised for even more growth in the near future. As we continue to grow, the one thing that will never change is our commitment to patients.